La Jolla Pharmaceutical (NASDAQ:LJPC) Issues Earnings Results, Misses Estimates By $0.16 EPS

La Jolla Pharmaceutical (NASDAQ:LJPCGet Rating) posted its earnings results on Monday. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.16), Fidelity Earnings reports. La Jolla Pharmaceutical had a net margin of 25.96% and a negative return on equity of 27.07%.

NASDAQ:LJPC traded up $0.04 on Tuesday, reaching $4.20. The company’s stock had a trading volume of 100 shares, compared to its average volume of 66,331. La Jolla Pharmaceutical has a 12-month low of $3.40 and a 12-month high of $5.69. The firm has a market cap of $107.60 million, a price-to-earnings ratio of 7.30 and a beta of 1.94. The stock has a 50 day moving average price of $4.18 and a 200 day moving average price of $4.30.

Separately, StockNews.com assumed coverage on La Jolla Pharmaceutical in a research report on Thursday, March 31st. They issued a “buy” rating on the stock.

A number of large investors have recently bought and sold shares of LJPC. Renaissance Technologies LLC acquired a new stake in shares of La Jolla Pharmaceutical in the third quarter valued at $183,000. Citadel Advisors LLC grew its stake in shares of La Jolla Pharmaceutical by 37.7% in the fourth quarter. Citadel Advisors LLC now owns 61,977 shares of the biopharmaceutical company’s stock valued at $288,000 after buying an additional 16,959 shares in the last quarter. Northern Trust Corp grew its stake in shares of La Jolla Pharmaceutical by 5.3% in the first quarter. Northern Trust Corp now owns 80,053 shares of the biopharmaceutical company’s stock valued at $341,000 after buying an additional 4,047 shares in the last quarter. State Street Corp grew its stake in shares of La Jolla Pharmaceutical by 4.2% in the first quarter. State Street Corp now owns 98,941 shares of the biopharmaceutical company’s stock valued at $422,000 after buying an additional 3,962 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of La Jolla Pharmaceutical by 4.8% in the first quarter. Bank of New York Mellon Corp now owns 127,084 shares of the biopharmaceutical company’s stock valued at $543,000 after buying an additional 5,781 shares in the last quarter. Institutional investors own 97.06% of the company’s stock.

La Jolla Pharmaceutical Company Profile (Get Rating)

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older.

Further Reading

Earnings History for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.